A probiotic way to say no to Diabetes: Probiotic MIYAIRI 588-based therapy for diabetes (TIDM): Probiotic Clostridium butyricum MIYAIRI 588 (CBM588) increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 17/December/2018, 11.58 pm

Probiotic-based therapy for arthritic pain: Probiotic Lactobacillus  rhamnosous PB01 (DSM-14870) increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 17/December/2018, 11.51 pm
December 17, 2018
A probiotic way to say no to arthritic pain: Probiotic VSL#3 increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 18/December/2018, 12.05 am
December 17, 2018
Show all

Introduction: What they say

A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, AL shows that “miR-204 Controls Glucagon-Like Peptide 1 Receptor Expression and Agonist Function.” This research paper was published, in the 3 November 2017 issue of the journal “Diabetes” [One of the best research journals in diabetic research with an I.F of 10 plus], by Prof. Shalev A, Jo S and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: A probiotic way to say no to Diabetes: Probiotic MIYAIRI 588-based therapy for diabetes (TIDM): Probiotic Clostridium butyricum MIYAIRI 588 (CBM588) increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) more than 422 million people worldwide are affected by Diabetes mellitus (DM); (2) Diabetes is going to be one of the top 10 causes of death by 2030; (3) the life-long painful injection/drug treatment is required to treat DM; (4) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, diabetes.


What is known?

Prof. Shalev A’s research team has recently shown that:(1) MiRNA-204, the highly expressed miRNA in ß-cells, inhibits GLP1R expression; (2) deletion of miR-204: (a) increases cAMP production; (b) increases insulin secretion; (c) augments response to GLP1R activators or agonists; and (d) protects against diabetes; (3) deletion of thioredoxin-interacting protein, the upstream regulator of miR-204, (a) increases GLP1R expression; (b) ameliorates glucose intolerance; (c) improves cAMP production; (d) increases insulin secretion; and (e) protects against diabetes, suggesting that decreasing the expression of MiR-204 or its upstream regulator thioredoxin-interacting protein may promote insulin sensitivity, and alleviate TIIDM.


From Research findings to Therapeutic opportunity:

This study suggests, for the first time, with a detailed mechanistic insight, a probiotic-based therapy for Weight loss and TIIDM. Probiotic Clostridium butyricum MIYAIRI 588 (CBM588), by increasing the expression of its target gene, it may increase the expression of GLP1R and Caveolin-1 (CAV-1). Thereby, it may: (1) increase pancreatic beta-cell proliferation; (2) increase the expression of genes that promote insulin sensitivity and insulin secretion; (3) promote weight loss; (4) augment energy expenditure; (5) decrease metabolic stress; and (6) promote energy homeostasis (Fig.1). Thus, pharmacological formulations encompassing Probiotic Clostridium butyricum MIYAIRI 588 (CBM588), either alone or in combination with other drugs” may be used to treat TIIDM (Figure 2).

Figure 1. Mechanistic insights into how Probiotic VSL#3 function as an antidiabetic agent. Probiotic VSL#3 , by up regulating its target genes, it may: a) increase cAMP levels; b) increase insulin sensitivity; c) increase increase secretion; and d) attenuate hyperglycemia.

Figure 2. Probiotic Clostridium butyricum MIYAIRI 588 (CBM588)  functions as an antidiabetic agent. Probiotic VSL#3 may function as an antidiabetic agent through induction of Cav1 and GLP1R.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed information: How does Probiotic Clostridium butyricum MIYAIRI 588 (CBM588) increase the expression of GLP1R and CAV-1?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org

* Research cooperation


References:

Web: http://genomediscovery.org  or http://newbioideas.com

Citation: Boominathan, L., A probiotic way to say no to Diabetes: Probiotic MIYAIRI 588-based therapy for diabetes (TIDM): Probiotic Clostridium butyricum MIYAIRI 588 (CBM588) increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 17/December/2018, 11.58 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

 

 

Comments are closed.